Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 13/20 | 0.62 |
| ▸ | FGFR2 | P21802 | 12/20 | 0.62 |
| ▸ | FGFR3 | P22607 | 12/20 | 0.62 |
| ▸ | BTK | Q06187 | 4/20 | 0.59 |
| ▸ | EGFR | P00533 | 2/20 | 0.59 |
| ▸ | LCK | P06239 | 2/20 | 0.59 |
| ▸ | JAK3 | P52333 | 2/20 | 0.59 |
| ▸ | ITK | Q08881 | 2/20 | 0.59 |
| ▸ | FGFR4 | P22455 | 9/20 | 0.56 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16701573 | 0.92 | BTK (0.56) | FGFR1FGFR2FGFR3BTKEGFR | |
| SCHEMBL16702077 | 0.89 | PIK3CD (0.63) | FGFR1BTKEGFRLCKJAK3 | |
| SCHEMBL16701791 | 0.89 | FGFR1 (0.60) | FGFR1FGFR2FGFR3BTKEGFR | |
| SCHEMBL16701794 | 0.89 | PIK3CD (0.61) | FGFR1FGFR2FGFR3BTKEGFR | |
| SCHEMBL16702048 | 0.87 | BTK (0.55) | FGFR1FGFR2FGFR3BTKEGFR | |
| SCHEMBL16702106 | 0.87 | FGFR1 (0.53) | FGFR1FGFR2FGFR3BTKEGFR | |
| SCHEMBL16702423 | 0.85 | FGFR1 (0.55) | FGFR1FGFR2FGFR3BTKEGFR | |
| SCHEMBL16701939 | 0.85 | BTK (0.56) | FGFR1FGFR2FGFR3BTKEGFR | |
| SCHEMBL16701754 | 0.85 | FGFR1 (0.46) | FGFR1FGFR2FGFR3BTKEGFR | |
| SCHEMBL16701955 | 0.85 | FGFR2 (0.62) | FGFR1FGFR2FGFR3BTKEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160272645-A1 | Heterocyclic Compounds and Methods of Use | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-09-22 | — | — | US | claimed |
| WO-2015069441-A1 | PYRAZOLO-, IMIDAZOLO- AND PYRROLO-PYRIDINE OR -PYRIMIDINE DERIVATIVES AS INHIBITORS O BRUTONS KINASE (BTK) | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-05-14 | — | — | WO | claimed |
| US-20160272645-A1 | Heterocyclic Compounds and Methods of Use | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-09-22 | — | — | US | disclosed |
| US-20160272645-A1 | Heterocyclic Compounds and Methods of Use | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-09-22 | — | — | US | disclosed |
| WO-2015069441-A1 | PYRAZOLO-, IMIDAZOLO- AND PYRROLO-PYRIDINE OR -PYRIMIDINE DERIVATIVES AS INHIBITORS O BRUTONS KINASE (BTK) | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160272645-A1 | Heterocyclic Compounds and Methods of Use | BTK, PIK3CD, PIK3CB | FGFR1 2569/4885FGFR2 1759/4885FGFR3 1469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.